A method of cross-linking collagen present in a collagenous tissue comprising contacting the collagenous tissue with an amount of a formaldehyde releasing agent effective to crosslink the collagen is provided. A method of inhibiting loss of structural integrity of a collagenous tissue during transplantation-related transport comprising contacting the collagenous tissue with an amount of a formaldehyde releasing agent effective to inhibit loss of structural integrity of the collagenous tissue is also provided. A composition for ophthalmic administration comprising a formaldehyde releasing agent, sodium bicarbonate, and ophthalmically suitable carriers or excipients is also provided. Finally, a method of altering the refractive power of a cornea comprising contacting the cornea with a formaldehyde releasing agent so as to effect cross-linking in the cornea and thereby alter the refractive power of the cornea is provided.

A method of cross-linking collagen present in a collagenous tissue comprising contacting the collagenous tissue with an amount of a formaldehyde releasing agent effective to crosslink the collagen is provided. A method of inhibiting loss of structural integrity of a collagenous tissue during transplantation-related transport comprising contacting the collagenous tissue with an amount of a formaldehyde releasing agent effective to inhibit loss of structural integrity of the collagenous tissue is also provided. A composition for ophthalmic administration comprising a formaldehyde releasing agent, sodium bicarbonate, and ophthalmically suitable carriers or excipients is also provided. Finally, a method of altering the refractive power of a cornea comprising contacting the cornea with a formaldehyde releasing agent so as to effect cross-linking in the cornea and thereby alter the refractive power of the cornea is provided.

A method of cross-linking collagen present in a collagenous tissue comprising contacting the collagenous tissue with an amount of a formaldehyde releasing agent effective to crosslink the collagen is provided. A method of inhibiting loss of structural integrity of a collagenous tissue during transplantation-related transport comprising contacting the collagenous tissue with an amount of a formaldehyde releasing agent effective to inhibit loss of structural integrity of the collagenous tissue is also provided. A composition for ophthalmic administration comprising a formaldehyde releasing agent, sodium bicarbonate, and ophthalmically suitable carriers or excipients is also provided. Finally, a method of altering the refractive power of a cornea comprising contacting the cornea with a formaldehyde releasing agent so as to effect cross-linking in the cornea and thereby alter the refractive power of the cornea is provided.

The present disclosure relates, in some embodiments, to an immunogenic compositions for the treatment of cancer, methods of preparing an immunogenic composition for the treatment of cancer, and methods of treating cancer subjects with an immunogenic composition.

Some embodiments of the present disclosure relate to an immunogenic composition operable as a treatment of cancer in a subject having a subject weight, the immunogenic composition including: an immunoactive tissue extract comprising a protein composition, wherein the immunogenic composition has a final concentration of the protein composition of about 6 mg to about 10 mg of the protein composition per kg of the subject weight; an immune response activator comprising a BCG solution, wherein the immunogenic composition has a final concentration of the immune response activator of about 0.525 to about 0.725 mg of the BCG solution per mL of the immunogenic composition; and an immune response mitigator comprising a formaldehyde solution, wherein the immunogenic composition has a final concentration of the formaldehyde solution of about 0.005% to about 0.035%.

The present disclosure relates, in some embodiments, to an immunogenic compositions for the treatment of cancer, methods of preparing an immunogenic composition for the treatment of cancer, and methods of treating cancer subjects with an immunogenic composition.

Some embodiments of the present disclosure relate to an immunogenic composition operable as a treatment of cancer in a subject having a subject weight, the immunogenic composition including: an immunoactive tissue extract comprising a protein composition, wherein the immunogenic composition has a final concentration of the protein composition of about 6 mg to about 10 mg of the protein composition per kg of the subject weight; an immune response activator comprising a BCG solution, wherein the immunogenic composition has a final concentration of the immune response activator of about 0.525 to about 0.725 mg of the BCG solution per mL of the immunogenic composition; and an immune response mitigator comprising a formaldehyde solution, wherein the immunogenic composition has a final concentration of the formaldehyde solution of about 0.005% to about 0.035%.

There is provided a composition comprising an organic material and at least a first surfactant which following addition of an aqueous solution to the composition can form a biphasic system, wherein the biphasic system is useful for the treatment of or prevention of hoof infections. Also provided is a biphasic system useful for the treatment of or prevention of hoof infections, wherein the biphasic system comprises the composition and an aqueous phase wherein the composition is dispersed as droplets within the aqueous phase.

There is provided a composition comprising an organic material and at least a first surfactant which following addition of an aqueous solution to the composition can form a biphasic system, wherein the biphasic system is useful for the treatment of or prevention of hoof infections. Also provided is a biphasic system useful for the treatment of or prevention of hoof infections, wherein the biphasic system comprises the composition and an aqueous phase wherein the composition is dispersed as droplets within the aqueous phase.

The invention relates to the field of experimental medicine and concerns the creation of a novel effective agent for correcting mitochondrial dysfunction in laboratory animals. The claimed invention addresses the technical problem of creating an effective and easy-to-use agent for the experimental correction of mitochondrial dysfunction. The technical result consists in increasing mitochondrial membrane potential and increasing neutrophil oxygen-dependent metabolism. This technical result is achieved by using an immunomodulatory agent for intramuscular injection, containing formaldehyde in an amount of 0.076-0.078% in an isotonic solution of sodium chloride at a concentration of 0.85-0.95%, as an agent for increasing mitochondrial membrane potential and increasing neutrophil oxygen-dependent metabolism.

The invention relates to the field of experimental medicine and concerns the creation of a novel effective agent for correcting mitochondrial dysfunction in laboratory animals. The claimed invention addresses the technical problem of creating an effective and easy-to-use agent for the experimental correction of mitochondrial dysfunction. The technical result consists in increasing mitochondrial membrane potential and increasing neutrophil oxygen-dependent metabolism. This technical result is achieved by using an immunomodulatory agent for intramuscular injection, containing formaldehyde in an amount of 0.076-0.078% in an isotonic solution of sodium chloride at a concentration of 0.85-0.95%, as an agent for increasing mitochondrial membrane potential and increasing neutrophil oxygen-dependent metabolism.